Baker Bros. Advisors LP Nurix Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $7.52 Billion
- Q2 2024
A detailed history of Baker Bros. Advisors LP transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 3,882,125 shares of NRIX stock, worth $90.6 Million. This represents 1.08% of its overall portfolio holdings.
Number of Shares
3,882,125
Previous 3,882,125
-0.0%
Holding current value
$90.6 Million
Previous $57.1 Million
41.97%
% of portfolio
1.08%
Previous 0.72%
Shares
3 transactions
Others Institutions Holding NRIX
# of Institutions
183Shares Held
66.4MCall Options Held
40.9KPut Options Held
106K-
Black Rock Inc. New York, NY6.82MShares$159 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.42MShares$103 Million6.02% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.99MShares$93.1 Million2.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.63MShares$84.6 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA3.2MShares$74.7 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $1.1B
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...